Nama's AI scorecard currently rates Zimmer Biomet Buy (6.3 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is ZBH's P/E ratio?

Zimmer Biomet trades at a trailing price-to-earnings ratio of 12.4.

When does ZBH report earnings?

Zimmer Biomet's next scheduled report is on Feb 10, 2027. Analysts expect EPS of $2.49.

What is the ZBH price target?

The median analyst price target from 21 analysts is $106.00, with a range of $93.00 – $125.00.

Is ZBH Shariah compliant?

Nama's AAOIFI-style screen reads Zimmer Biomet as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Does ZBH pay a dividend?

Yes — Zimmer Biomet's dividend yield is 0.9%.

Nama Insights

Zimmer Biomet (ZBH)

Healthcare · Medical Devices · NYSE

S&P 500

Zimmer Biomet (ZBH) is a Healthcare company in the Medical Devices industry. It has a market capitalization of $19.98B, a trailing price-to-earnings ratio of 12.4 and a free-cash-flow yield of 6.8%. Over the most recent reported fiscal year, revenue grew 7.2% and free cash flow per share grew 27.6%. Nama's AI scorecard rates it Buy, 6.3 out of 10. On 12-month momentum it ranks in the lagging band of its market.

AI scorecard

Buy · 6.3/10

Positive, at the low end of Buy. As of Nov 7, 2026.

Momentum

Lagging · -0.0% over 12 months ex. last

Second-worst fifth of its market on the past year's move.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-29.2%

How far the last close sits under the highest price of the past five years.

Market cap	$19.98B
Trailing P/E	12.4
Price / book	1.6
Price / sales	2.4
FCF yield	6.8%
Dividend yield	0.9%
Gross margin	69.9%
Operating margin	16.3%
Net margin	9.5%
Revenue growth (YoY)	+7.2%
Revenue growth (3-yr annual)	+5.8%
EPS growth (YoY)	+2.5%
FCF/share growth (YoY)	+27.6%
Beta	0.5
Exchange	NYSE
Sector	Healthcare
Industry	Medical Devices

ZBH earnings

Next report: Feb 10, 2027 (Q4 2026, EPS estimate $2.49). Beat the EPS estimate in 4 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 4, 2026	$1.90	$1.88	+1.1%	$2.06B
Q2 2026	Aug 5, 2026	$2.07	$2.01	+3.0%	$2.18B
Q1 2026	Apr 28, 2026	$2.09	$1.86	+12.4%	$2.09B
Q4 2025	Feb 10, 2026	$2.42	$2.40	+0.8%	$2.24B

ZBH analyst price target

Median target $106.00 from 21 analysts, ranging $93.00 – $125.00.

Medical Devices peers

Ticker	Company	Market cap	P/E
ABT	Abbott Laboratories	$190.39B	20.4
MDT	Medtronic	$130.22B	17.8
SYK	Stryker	$124.06B	22.8
BSX	Boston Scientific	$61.96B	13.4
EW	Edwards Lifesciences	$58.73B	34.7
GEHC	GE HealthCare Technologies	$37.25B	16.8
PHG	Koninklijke Philips	$29.67B	15.2
DXCM	DexCom	$29.62B	29.7

Explore live ZBH data on Nama Insights →

Recent Congressional trades

Zimmer Biomet trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
Alan Armstrong	Senate	Buy	$1,001 - $15,000	Jul 21, 2026
Rob Bresnahan	House	Sell	$1,001 - $15,000	May 31, 2025
Rob Bresnahan	House	Buy	$1,001 - $15,000	May 8, 2025
Julie Johnson	House	Sell	$1,001 - $15,000	Mar 12, 2025
John F Reed	Senate	Sell	$1,001 - $15,000	—
John F Reed	Senate	Sell	$1,001 - $15,000	—

ZBH FAQ

Is ZBH a buy?: Nama's AI scorecard currently rates Zimmer Biomet Buy (6.3 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is ZBH's P/E ratio?: Zimmer Biomet trades at a trailing price-to-earnings ratio of 12.4.
When does ZBH report earnings?: Zimmer Biomet's next scheduled report is on Feb 10, 2027. Analysts expect EPS of $2.49.
What is the ZBH price target?: The median analyst price target from 21 analysts is $106.00, with a range of $93.00 – $125.00.
Is ZBH Shariah compliant?: Nama's AAOIFI-style screen reads Zimmer Biomet as Not Shariah Compliant. At least one of the three ratios or the industry test failed.
Does ZBH pay a dividend?: Yes — Zimmer Biomet's dividend yield is 0.9%.